Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Ruxolitinib cream, a topical JAK inhibitor, used either twice daily or as needed, has proven effective as a nonsteroidal monotherapy for relieving signs and symptoms of AD, also known as eczema, a common condition that causes itchy, dry and inflamed skin.
AD usually begins in childhood but can start at any age, according to the American Academy of Dermatology.
The poster, which displayed data of an ongoing phase 3 study of children with mild to moderate AD, is aimed to evaluate the efficacy of ruxolitinib cream use in children with the condition.
In this randomized, double-blind study, participants are randomly assigned to use either ruxolitinib cream at different strengths (0.75% ,1.5%) or a neutral vehicle cream to monitor how effective the creams are after 8 weeks of use.
If participants haven't had any safety issues by then, they will continue using the same cream for another 44 weeks to see its long-term safety.
If participants were initially using the vehicle cream, they will then be randomly assigned to one of the two ruxolitinib cream groups for the rest of the study.
So far, it was found that patients who used either 0.75% or 1.5% ruxolitinib cream experienced improvement in their condition compared to those using the vehicle cream, starting as early as week 2 and lasting through week 8.
Additionally, by week 8, patients at different levels of AD severity showed similar improvements in skin condition and itchiness.
Out of the 330 patients enrolled, 12.7% discontinued treatment within the initial 8-week period, mainly due to reasons such as withdrawing from the study or being lost to follow-up.
Overall, it was found that both strengths of ruxolitinib cream were well tolerated among children, with only a few reporting mild reactions. No serious side effects or events suggesting systemic JAK inhibition were observed during the study.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More
Reasons for attending the AAD meeting | AAD 2024
March 7th 2024John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
Read More